Moderna shares hit 52‑week high as Nasdaq‑100 re‑entry coincides with NIH cancer‑vaccine drive

Moderna Inc.'s shares surged to a fresh 52‑week peak on Tuesday, marking the biotech firm's strongest performance in the past twelve months. The rally came shortly after the company's stock was reinstated in the Nasdaq‑100 index, a move that typically draws attention from large institutional investors.

The timing also aligned with a new initiative from the U.S. National Institutes of Health (NIH) that aims to accelerate development of cancer‑targeted vaccines. Analysts noted that the NIH's heightened focus on immunotherapy could boost long‑term growth prospects for companies like Moderna that specialize in messenger‑RNA technology.

While the price jump reflects optimism, market observers cautioned that the stock remains subject to broader biotech volatility and regulatory developments. No specific price or percentage change was disclosed in the source report, but the dual catalyst of index re‑entry and federal research support was highlighted as the primary driver of the upward move.